

Advanced eMAGE for highly efficient combinatorial editing of a stable genome

Zhuobin Liang^{1,3,*}, Eli Metzner^{1,3} and Farren J. Isaacs^{1,2,3,*,+}

¹Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT 06520, USA

²Department of Biomedical Engineering, Yale University, New Haven, CT 06520, USA

³Systems Biology Institute, Yale University, West Haven, CT 06516, USA

⁺Lead Contact

*Correspondence addressed to: FJI (farren.isaacs@yale.edu) or ZL (zhuobin.liang@yale.edu)

Abstract

Eukaryotic multiplex genome engineering (eMAGE) offers a powerful tool to generate precise combinatorial genome modifications in *Saccharomyces cerevisiae*. We optimize the design of synthetic oligonucleotides and enrichment of edited populations to increase editing frequencies up to 90%, reduce workflow time by 40%, and engineer a tunable mismatch repair system to lower the rate of spontaneous mutations ~17-fold. These advances transiently evade genome maintenance to introduce multiple edits at high efficiencies in a stable genetic background, expanding utility of eMAGE in eukaryotic cells.


Main

Genome editing has empowered researchers to elucidate causal links between genotype and phenotype, enact targeted genetic modifications to reprogram cellular behavior, and design organisms with synthetic genomes¹. Conventional genome editing technologies use programmable endonucleases, including zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and CRISPR-Cas nucleases, to generate site-specific DNA double-strand breaks (DSBs) in the genome. Subsequent DSB repair by endogenous machinery can introduce mutagenic gene disruptions via non-homologous end joining (NHEJ) or precise modifications via homology directed repair (HDR)². Recent advances in expression of multiple guide RNAs and orthologous Cas nucleases have enabled multiplex CRISPR-Cas editing of 3-10 sites simultaneously³. In addition, several methods derived from CRISPR explore fusion of nuclease-deficient Cas proteins to a variety of DNA effectors, such as deaminases^{4,5}, error-prone polymerases⁶, transposases^{7,8} and reverse transcriptases⁹, to develop DSB-independent, alternative genome editing tools (*e.g.*, Base editing^{4,5} and Prime editing⁹). However, for applications requiring generation of multisite (>10) combinatorial genomic alterations with base-pair (bp)-level precision, conventional or modified CRISPR-based genome editing systems are inadequate due to inherent limitations¹⁰, such as off-target effects, cytotoxicity, editing accuracy, and multiplexing ceiling.

Limitations in the scale and precision of current genome editing methods have motivated our recent work to develop a nuclease-independent eukaryotic multiplex genome engineering (eMAGE) platform¹¹, which directs the annealing of multiple ~90-nt single-stranded oligodeoxynucleotides (ssODNs) at the DNA replication fork to rapidly generate precise combinatorial (10^5 - 10^6) genome modifications with up to 40% efficiency across many (10 - 10^2) loci in targeted genomic regions of *S. cerevisiae* (**Fig. 1a**). The eMAGE method uses a counter-selectable marker (*e.g.*, *URA3*) adjacent to the targeted genomic region to enrich ssODN-edited cells via a co-selection strategy^{11,12} (**Fig. 1b**). Like other ssODN-mediated genome editing methods¹³⁻¹⁵, eMAGE editing efficiency is greatly enhanced by inactivation of genes required for DNA mismatch repair (MMR)¹¹. However, such constraints reduce genome stability, which could lead to the accumulation of unintended secondary mutations from unresolved DNA replication errors and spontaneous lesions, and requires prior modifications of the genome (*e.g.*, deletion of MMR genes).

In this study, we describe several key advances in eMAGE to address these limitations and enhance editing efficiency (**Fig. 1b**). First, we redesigned the eMAGE protocol and editing assay, substantially reducing experimental workflow time by two days, or 40%, and permitting rapid analysis

of a larger number of edited cells with improved precision. Second, we performed systematic optimization of ssODN concentration, ratio and modification, as well as implemented a new co-selection strategy, leading to a striking increase in eMAGE efficiency with up to ~90% edited cells in a population. Finally, we developed a system for transient and controllable MMR suppression by engineering expression of dominant negative MMR mutants, achieving high-efficiency editing in DNA repair-proficient cells with enhanced genome stability and reduced frequency of unintended secondary mutations.




We first set out to reduce co-selection time and increase assay throughput by developing an improved editing reporter compatible with flow cytometry to accelerate the eMAGE workflow. To

measure eMAGE editing allelic replacement frequency (ARF), we previously used a *URA3-ADE2* reporter¹¹ assay with a 5.5-day turnaround time to quantify *ADE2* ARF as the percentage of *ade2* edited cells (red colonies) on culture plates containing 5-fluoroorotic acid (5-FOA, a chemical compound that counterselects *ura3* cells). The redesigned eMAGE reporter harbors *URA3* and *yEmRFP* genes each carrying a predefined frameshift (FS) located in a previously characterized genomic locus¹¹ of replication origin ARS1516 in chromosome XV (**Fig. 1c**). Yeast cells co-transfected with ssODNs restoring the correct reading frames of both *URA3* and *yEmRFP* were co-selected in liquid medium lacking uracil and analyzed via flow cytometry to determine the frequency of RFP positive cells, which represents eMAGE ARF (**Fig. 1d**). The new *URA3*(FS)-*RFP*(FS) reporter provides three advantages over the previous *URA3-ADE2* reporter¹¹. First, it reduces culturing time needed for eMAGE co-selection from four to two days by making use of the more robust positive *URA3* selection and rapid RFP readout (**Fig. 1d**), and avoiding laborious plating and colony screening procedures. Second, it eliminates interference from secondary mutations due to the extremely low frequency of spontaneous frameshift correction (which we did not observe), rendering co-selection more stringent by avoiding background 5-FOA resistant mutants (~10% of total *ura3* colonies¹¹) that are unrelated to ssODN editing. Third, it facilitates rapid (~30 seconds per sample) and more accurate quantification of eMAGE editing frequency via analyzing a larger population by flow cytometry (>10⁵ flowed cells vs. 10²-10³ colonies), resulting in a significantly improved assay throughput (>100 samples per hour). Together, this fluorescent reporter system permits convenient, fast and accurate comparison of eMAGE ARF among diverse conditions, establishing a facile system for optimization.


Using the fluorescent reporter system, we next attempted to optimize eMAGE ARF by investigating a wide range of concentrations between ssODNs targeting the edited locus (*RFP*) and the co-selection marker (*URA3*). Holding concentration of the RFP-ssODN at 10 μ M and total ssODN concentration at 20 μ M by supplementing a non-targeting ssODN, we decreased concentration of the *URA3*-ssODN and observed up to ~40% ARF in the *RFP* gene. This is a significant increase over the 25% baseline using the previous protocol¹¹, in which ssODN concentration is 10 μ M for both the co-selection marker (*URA3*) and editing targeted site (*RFP*) (**Fig. 1e**, group 1). Conversely, samples with a decreased RFP- to *URA3*-ssODN concentration ratio showed reduced eMAGE ARF in the range of ~13-22% (**Fig. 1e**, group 2). These results suggest that eMAGE ARF can be enhanced by limiting the cellular availability of ssODN targeting the selectable marker to increase the stringency of co-selection. With the same ratio of ssODN concentrations, total concentration of ssODNs through 40 μ M positively correlated

with eMAGE ARF up to ~48% (**Fig. 1e**, compare groups 1, 3, 4 and 5). Further increase of RFP ssODN concentration to 60, 80 or 100 μ M showed no further enhancement in eMAGE ARF (**Fig. 1e**, group 6), despite a slight increase in the RFP positive frequency in ssODN-transfected cells prior to *URA3* co-selection (**Extended Data Fig. 1a**), suggesting that eMAGE ARF reaches an efficiency ceiling with *URA3*-ssODN at ~40 μ M. Given that concentration of *URA3*-ssODN also positively influences the initial number of *URA3* cells (**Extended Data Fig. 1b**) and the total ssODN concentration negatively correlates with cell survival after electroporation (**Extended Data Fig. 1c**), we converged on optimal ssODN conditions: 20-60 μ M total ssODN with a 20:1 ratio of ssODNs targeting edited site(s) and the co-selection marker (e.g., **Fig. 1e**, condition 22). We also attempted to increase the nuclease resistance of ssODNs by modifying their terminal nucleotides at both ends with phosphorothioate bonds and observed a minor but statistically significant ARF increase of ~5% over unmodified ssODNs at 40 and 80 μ M (**Extended Data Fig. 1d**).

We previously observed that eMAGE ARF decreases as the distance between edited sites and the co-selection marker increases: ~40% at 1 kb, to ~15% at 5 kb, to ~5% at 20 kb¹¹. We hypothesize that flanking the targeted genomic region with two co-selection markers would sustain high levels of multisite editing across a longer genomic locus. To test this hypothesis, we constructed a five-gene construct *URA3*(FS)-*BGR*(FS)-*ADE2*(FS), comprising three fluorescent reporters (*ymTagBFP2*, *ymUkG1* and *yEmRFP*) flanked by two selectable markers (*URA3* and *ADE2*), each of which bears a predefined frameshift mutation (**Fig. 2a**). Applying the ssODN concentration and ratio from the optimization experiments described above (1 μ M for each co-selection marker and 20 μ M for each fluorescent reporter), we observed that co-selection using both *URA3* and *ADE2* markers led to significantly higher eMAGE ARF (50-70%) in all three fluorescent reporters, as compared to co-selection using a single marker (**Fig. 2b**). Analysis of eMAGE multiplex editing further revealed that dual-marker co-selection enriched significantly more double- and triple-edited cells (~60% vs. ~30-40%) and dramatically reduced the unedited sub-population from ~30% to ~5% (**Fig. 2c**). Using the three fluorescent genes in the eMAGE reporter, we further compared three genetic architectures for dual-marker co-selection by differentially gating the flow cytometry data to determine how the relative positions of the co-selection markers affect ARF (**Extended Data Fig. 2a**). We found that dual-marker co-selection in any placement configuration outperformed single-marker co-selection, and that markers flanking the targeted site resulted in the highest ARF (**Extended Data Fig. 2b**).



Consistent with prior observations^{11, 13}, we confirmed that deletion of *MSH2* (*msh2Δ*) increased editing frequency three- to five-fold in all five markers of the multi-gene *URA3(FS)-BGR(FS)-ADE2(FS)* reporter (**Fig. 2a**) after transfection of a pool of five ssODN at the optimal concentrations (*i.e.*, 1 μ M for *URA3*, *ADE2* and 20 μ M for *B-*, *G-*, *RFP* genes) (**Extended Data Fig. 3**). This *msh2Δ* background also led to a 10-fold increase of double-edited *URA3*, *ADE2* cells, bolstering the dual-marker co-selection strategy. To maintain high eMAGE ARF (~90% edited) while circumventing permanent MMR inactivation, we adopted a similar approach used successfully for MAGE in bacteria¹⁶: transient expression of dominant negative mutants of MMR proteins (MMR-DN) in DNA repair-proficient cells to temporarily suppress MMR prior to ssODN electroporation (**Fig. 3a**). To gain tighter



control of the expression level of MMR-DN mutants and enhance the reproducibility of this method, we modified a previously reported β-estradiol inducible expression system by stably integrating the estradiol-responsive transcription activator (GEM) expression cassette in a defined genomic locus (YFL033C¹⁸) to constitutively express GEM at a moderate level in order to achieve tunable induction of MMR-DN upon β-estradiol titrations. We then empirically characterized this regulator using RFP expression which showed a dynamic range of inducible expression levels with no detectable uninduced basal expression. (**Extended Data Fig. 4a**).

Next, we screened nine different MMR-DN mutants from three subunits (MSH2, MSH6 and MLH1) of the yeast mismatch repair MutS complexes, which have shown strong dominant negative effects in previous studies¹⁹⁻²¹, together with three wild-type subunit proteins (**Extended Data Table 1**),

via episomal overexpression in a MMR-proficient strain (**Extended Data Fig. 4b**) harboring the *URA3(FS)-BGR(FS)-ADE2(FS)* reporter (**Fig. 2a**). Among the 12 tested MMR protein variants, moderate expression (β -estradiol: 0.4 μ M) of MSH2-DN mutants¹⁹ led to the highest frameshift correction frequencies in three fluorescent genes, followed by MLH1-WT (for which overexpression was reported to have a DN effect²⁰) and MLH1-DN mutants²⁰, while expression of MSH6-DN mutants²¹ surprisingly showed no significant dominant negative effect in our assay (**Extended Data Fig. 4c**). Notably, we screened MMR-DN candidates using the frequency of fluorescent cells in ssODN-transfected population prior to co-selection, which directly reflects the efficiency of ssODN incorporation and is thus more sensitive to MMR suppression than the post co-selection eMAGE ARF.

We then selected MSH2-GGDD and MLH1-WT for further optimization by fine-tuning the expression level of both mutants alone and in combination. Expression of MSH2-GGDD alone at relatively high levels (β -estradiol: 0.6-1 μ M) or in combination with MLH1-WT at relatively low levels (β -estradiol: 0.2-0.4 μ M) yielded similar frameshift correction frequency as the *msh2* Δ cells with no statistically significant difference (**Extended Data Fig. 4d**). Importantly, analysis of eMAGE multiplex editing demonstrated that three selected MMR-DN mutant expression conditions each confer proportions of unedited, single-, double-, and triple-positive cells indistinguishable from *msh2* Δ background (**Fig. 3b**). Interestingly, albeit having significantly less total edited cells than other strains with permanent or transient MMR inactivation, the MMR-proficient (WT) strain is capable of considerably improved eMAGE editing as compared to our prior results¹¹, due to the optimization of ssODN condition and the new eMAGE co-selection design described in this study (**Fig. 1 and 2**). This provides a new opportunity to conveniently apply the reported optimized conditions to enable eMAGE with modest efficiency in DNA repair-proficient cells independent of MMR modulation. Assessment of spontaneous mutation rate by Luria-Delbrück fluctuation analysis²² revealed that MMR-proficient cells carrying episomal MSH2-GGDD have a similar frequency of spontaneous mutations to wild-type cells, which can be transiently toggled to a level similar to *msh2* Δ cells upon MMR-DN expression (**Extended Data Table 2**, column A). Further analysis of data collected in this study demonstrates that tunable expression of MSH2-GGDD not only preserves wild-type levels of low spontaneous mutations (**Extended Data Table 2**, column B), but also inducibly enables *msh2* Δ levels of high-efficiency multiplex editing in a transiently relaxed genomic context with up to 10⁴ possible combinations of genomic diversity (**Extended Data Table 2**, column C-E).

In summary, this study accelerates the eMAGE editing workflow by ~40%, improves on-target editing efficiency up to 70% for single edits and >60% for multiplex editing, resulting in ~90% of cells carrying intended genomic modifications after one round of eMAGE. The engineered MMR system for transient suppression of DNA repair genes permits high-efficiency eMAGE editing in DNA repair-proficient cells, reducing unintended mutations by at least 4-fold during the editing process and ~17-fold in long-term outgrowth, thereby stabilizing the genome in eMAGE strains (**Fig. 1b**). We expect that these advances will empower eMAGE for tasks that demand precise and combinatorial diversification of targeted genetic elements with prolonged cultivation²³, such as protein engineering, molecular evolution, heterologous pathway optimization, and synthetic genome construction. Given the highly conserved nature of eukaryotic DNA replication and repair, we envision that the reported advances of eMAGE can guide subsequent development of analogous nuclease-independent genome editing technologies in other yeast and eukaryotic cells.

Methods

Strain construction. Yeast strains used in this study can be found in **Supplementary Table 1** and sequences of important genomic loci can be found in **Supplementary File 1**. To construct the yeast strain harboring the *URA3*(FS)-*RFP*(FS) eMAGE reporter (**Fig. 1c**), the *URA3* cassette of EMB101¹¹ was first replaced by a PCR product of *ymUkGI*²⁴(FS)-*yEmRFP*²⁵(FS) cassettes via standard homologous recombination (HR) and 5-FOA counterselection, resulting in yeast strain SZL149. Next a *URA3* cassette was reintroduced to replace the *ymUKGI*(FS) cassette via HR and uracil drop-out selection, resulting in strain SZL238 with *URA3-yEmRFP*(FS). Next a frameshift mutation was introduced in the *URA3* coding sequence by eMAGE with an ssODN, OZL327 (information of PCR primers can be found in **Supplementary Table 3**), followed by 5-FOA counterselection, resulting in strain SZL247. Finally, the *MSH2* gene was deleted by a *KanMX4* cassette conferring G418 (geneticin) resistance, resulting in strain SZL335 that was used in **Fig. 1e**. To construct strains capable of β -estradiol inducible expression, GEM effector expression cassette together with the *LEU2* marker was PCR amplified from pHES839¹⁷ (Addgene # 87941) using primers OZL348 and OZL349 and integrated downstream of the *YFL033C* locus of SZL149 and SZL281 (SZL149+*msh2* Δ), resulting in strain SZL281 and SZL308, respectively. To construct the yeast strains harboring the *URA3*(FS)-*BGR*(FS)-*ADE2*(FS) eMAGE reporter (**Fig. 2a**), *URA3-ymTagBFP2*(FS) cassettes (*ymTagBFP2*: codon-optimized *mTagBFP2*²⁶ for *S. cerevisiae* from this study, coding sequence can be found in **Supplementary File 1**)

was integrated between ARS1516 and the *ymUkGI*(FS) cassette of SZL281 and SZL308, resulting in strain SZL345 and SZL347, respectively. Next a frameshift mutation was introduced in the *URA3* and *ADE2* coding sequences by a round of eMAGE with ssODN OZL327 and OZL428, resulting in strain SZL376 that was used in **Fig. 3b** and **Extended Data Fig. 3c,d** (MMR-WT), and strain SZL348 that was used in **Fig. 2b,c**, **Fig. 3b** and **Extended Data Fig. 3c,d** (*msh2Δ*). Yeast transformation was performed via the optimized PEG/lithium acetate protocol of the Wilson lab²⁷. All eMAGE reporter loci were sequence verified in the final strains.

Media. For yeast cultivation, cells were grown in nonselective YPADU liquid medium, which consists of YPD (10 g/l Yeast Extract, 20 g/l Peptone, 20 g/l Dextrose), supplemented with 40 mg/l adenine hemi sulfate, and 20 mg/l uracil. For auxotrophic selection, synthetic defined media with 2% glucose and drop-out of corresponding nutrients were used. For eMAGE with frameshifted markers, yeast was cultured in YPADU and recovered immediately after ssODN electroporation in YPADU with 0.5 M sorbitol. For culturing yeast strains carrying episomal expression vectors of MMR genes, YPADU with 200 µg/ml zeocin was used.

Plasmid cloning. Plasmids used in this study can be found in **Supplementary Table 2**. For inducible expression of MMR subunits, the *LEU2* cassette of pRSII425²⁸ (Addgene #35468) was replaced by a *Sh ble* cassette conferring zeocin resistance, resulting in a shuttle vector pRSII42B (this study) harbored in strain SZL134. Wild-type MMR genes (*MSH2*, *MSH6*, *MLH1*) were PCR amplified from genomic DNA of yeast strain BY4741²⁹ and cloned together with the bidirectional inducible *Gall-10* promoter into the PCR amplified pRSII42B backbone with OZL14 and OZL15 via Gibson assembly³⁰ using NEBuilder Kit (NEB, catalog E2621). MMR-DN mutant genes were subsequently generated via site-directed mutagenesis using either Q5 Site-Directed Mutagenesis Kit (NEB, catalog E0554S) or QuikChange Lightning Multi Site-Directed Mutagenesis Kit (Agilent, catalog 210515) according to the manufacturer protocols.

ssODN electroporation. ssODN electroporation was carried out using the previously reported protocol¹¹. In brief, a single colony was inoculated in a 2 ml starter culture of appropriate media and grown overnight to saturation. The next day, the culture was diluted 1:100 into 10 ml fresh media and grown until the OD600 is between 0.6 and 1.0 in 4-6 hours. Cells were then pelleted and incubated in

DTT-LiTE buffer (100 mM lithium acetate, 25 mM DTT, 500 mM hydroxyurea, 1x TE at pH 8.0) for 30 min at 30°C. Cells were then washed with ice cold water and 1 M sorbitol. The specified combinations and concentrations of ssODNs were prepared in 200 μ l 1 M sorbitol, and used to resuspend the washed cells. ssODN electroporation was carried out in a 2-mm cuvette (Biorad, catalog 1652086) at 1500 V, 25 μ F, 200 Ω . Immediately after electroporation, 1 ml eMAGE recovery medium (YPADU with 0.5 M sorbitol) was added to the cuvette, and the resuspended cells were added to a 15 ml culture tube containing 4 ml recovery media (final volume: 5 ml). Cells were then incubated at 30°C in a drum rotator (Fisher Scientific, catalog 14251- 228Q/ 232Q) for 12 hours prior to co-selection. Information of ssODNs used in this study can be found in **Supplementary Table 3**.

eMAGE co-selection. After overnight recovery after ssODN electroporation, 500 μ l of saturated culture was spun down, washed once with 1 ml sterile water, and transferred to 5 ml synthetic defined media with drop-out of auxotrophic nutrients based on the applicable selectable markers. This 10-fold diluted culture was first grown for 24 hours (single-marker co-selection) or 48 hours (dual-marker co-selection), then diluted 100-fold in 3 ml of the same synthetic defined media and incubated for another 24 hours to saturation. Sequential dilutions of 10- and 100-fold in two steps ensure that unedited cells represent less than 0.1% in co-selected population and therefore exert negligible influence on eMAGE ARF quantification, while making sure sampling errors in each dilution are within acceptable range (95% confidence level and 2% margin of error).

Flow cytometry analysis. Flow cytometry was carried out on BD FACSAria II. ymTagBFP2 was excited by the violet laser (405-nm) with the DAPI emission filter (450/40); ymUkG1 was excited by the blue laser (488-nm) with the FITC emission filter (530/30); yEmRFP was excited by the green laser (561-nm) with the Texas-Red emission filter (610/20). Yeast cells were washed and resuspended in 1x PBS prior to flow cytometry. Flow cytometry data were analyzed in FlowJo V10.

Cell survival assay. To measure the effect of ssODN concentration on cell survival, strain SZL335 was prepared the same way as in eMAGE and electroporated with representative concentrations of RFP- and URA3-ssODN. Immediately after ssODN electroporation, cells were plated onto YPADU plate with 0.5 M sorbitol and incubated at 30°C for 2 days. The number of colonies on each plate was counted and

normalized with the plating volumes and dilution factors to calculate the percentage of viable cells in each condition. Cell viability data were normalized to untreated cells (100 % viable).

β -estradiol inducible expression. The β -estradiol inducible system was constructed as above (Strain construction and Plasmid cloning). Constitutively expressed GEM translocates from cytosol to nucleus upon β -estradiol binding and activates transcription of the *Gall-10* promoter. β -estradiol (Sigma, catalog E1024) was prepared as a 10 mM stock solution in 100% ethanol, then diluted in media to working concentrations between 0 and 1 μ M. Titration of inducible expression levels was empirically determined using RFP expression. Plasmids were maintained via zeocin selection. RFP fluorescence and cell density (OD600) were measured in each β -estradiol concentration along a 24-hour time course using a BioTek plate reader (Synergy H1), and selective time points were plotted to visualize the dose-response curve of gene expression as shown in **Extended Data Fig. 4a**.

Fluctuation analysis. To quantify the spontaneous mutation rate of selective eMAGE strains in **Fig. 3d**, Luria-Delbrück fluctuation analysis was performed using a protocol modified from Lang²². In brief, a 2 ml starter culture was inoculated from a single colony in synthetic defined medium with drop-out of uracil and grown overnight to saturation. The next day different cultures were adjusted to the same OD of 1.0 and then diluted 5,000-fold in nonselective YPADU medium without or with β -estradiol in the specified concentration. 100 μ l of diluted yeast culture was added to each well of a 96-well plate at a seeding density of 200-600 cells and incubated at 30°C without shaking for 2 days until saturation. For each 96-well plate, cultures of 12 wells were pooled and used to determine the average number of cells per culture (N) by limited-dilution plating. The entire cultures (100 μ l) of the remaining 84 wells were spot plated on 5-FOA media and incubated at 30°C for 4 days. Mutation rate (μ): mutation events per cell per division or generation, was calculated using the $p0$ method with formula: $\mu = -\ln(p0)/N$, where $p0$ is the fraction of spot cultures with no colony.

Calculations of spontaneous mutation and eMAGE on-target editing. In **Extended Data Table 2**, spontaneous mutations rates of the *URA3* gene shown in column A were determined by the fluctuation analysis described above. Estimated numbers of spontaneous mutations shown in column B were calculated by normalizing the size of the *URA3* gene (804 bp) to S288c genome (12 mb) and multiplying the numbers of cell division in a typical round of eMAGE (~66 cell divisions) or after accumulative

cultivation of 10 days (~120 cell divisions). The cell division numbers were estimated based on the total time of yeast cultivation (*i.e.*, ~132 hours during eMAGE comprising 48-hour: isolated colony forming from frozen glycerol stock, 24-hour: eMAGE starter culture incubation, 12-hour: recovery post ssODN electroporation, and 48-hour: eMAGE co-selection) with an average 2-hour doubling time. The Average numbers of eMAGE on-target edits shown in column C were derived from data of the eMAGE multiplex editing experiments shown in **Fig. 3b** using formula: Avg. edits= $\Sigma[(\% \text{ of sub-population}) \times (\text{number of edits})]$, where ‘% of sub-population’ is the percentage of cells with either 0, 1, 2 or 3 edits. The number of double-edited URA3, ADE2 cells after ssODN electroporation and recovery shown in column D were calculated with cell viability data (~10% at 60 μ M ssODN) shown in **Extended Data Fig. 1c** and the URA3, ADE2 double frameshift correction frequency (~0.0015% for WT, ~0.015% for *msh2* Δ and MSH2-GGDD (β -E: 0.6 μ M)) shown in **Extended Data Fig. 3**. Total numbers of eMAGE edited sites shown in column F were calculated by multiplying the values in column C and D.

Statistical analysis. GraphPad Prism 8 was used for all statistical analysis. All data sets were generated with at least three replicates unless specified otherwise, and error bars are reported as mean $\pm$ SD. Ordinary one-way ANOVA Dunnett’s tests were used to measure significance of data of multiple groups, and unpaired t-tests were used to measure significance of data of two groups with confidence level cutoff of ns, not significant ≥ 0.05 , * $p < 0.05$ ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

Acknowledgements

We thank Dr. Edward Barbieri for sharing his collection of yeast strains and prior experience in eMAGE protocol optimization; Kenneth Nelson (Yale West Campus Analytical Core facility) for assistance with flow-cytometry experiments; Dr. Neta Dean (Stony Brook University) for sharing the yEmRFP construct. We are grateful to members of the Isaacs and Rinehart laboratories and Brett Lindenbach for their critical discussions and feedback; members of MacMicking, Chen and Levchenko laboratories for their advices and shared reagents for experiments; and members of the Lindenbach laboratory for reviewing the manuscript. We gratefully acknowledge support from the NSF (IOS-1923321) and Emerson Collective for funding.

Author Contributions

F.J.I and Z.L. conceived the experiments and directed the studies. Z.L. and E.M. conducted the experiments and analyzed data. Z.L., E.M. and F.J.I wrote the manuscript.

Competing Interests statement

The authors declare no competing interests.

Data availability

The plasmids generated from this study will be deposited on Addgene (<http://www.addgene.org>) upon publication. Yeast strains used in this study are available upon request to the corresponding authors.

References

1. Chari, R. & Church, G.M. Beyond editing to writing large genomes. *Nat Rev Genet* **18**, 749-760 (2017).
2. Haimovich, A.D., Muir, P. & Isaacs, F.J. Genomes by design. *Nat Rev Genet* **16**, 501-516 (2015).
3. McCarty, N.S., Graham, A.E., Studena, L. & Ledesma-Amaro, R. Multiplexed CRISPR technologies for gene editing and transcriptional regulation. *Nature communications* **11**, 1281 (2020).
4. Komor, A.C., Kim, Y.B., Packer, M.S., Zuris, J.A. & Liu, D.R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. *Nature* **533**, 420-424 (2016).
5. Gaudelli, N.M. et al. Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. *Nature* **551**, 464-471 (2017).
6. Halperin, S.O. et al. CRISPR-guided DNA polymerases enable diversification of all nucleotides in a tunable window. *Nature* **560**, 248-252 (2018).
7. Strecker, J. et al. RNA-guided DNA insertion with CRISPR-associated transposases. *Science* **365**, 48-53 (2019).
8. Klompe, S.E., Vo, P.L.H., Halpin-Healy, T.S. & Sternberg, S.H. Transposon-encoded CRISPR-Cas systems direct RNA-guided DNA integration. *Nature* **571**, 219-225 (2019).
9. Anzalone, A.V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. *Nature* **576**, 149-157 (2019).

10. Thompson, D.B. et al. The Future of Multiplexed Eukaryotic Genome Engineering. *ACS Chem Biol* **13**, 313-325 (2018).
11. Barbieri, E.M., Muir, P., Akhuetie-Oni, B.O., Yellman, C.M. & Isaacs, F.J. Precise Editing at DNA Replication Forks Enables Multiplex Genome Engineering in Eukaryotes. *Cell* **171**, 1453-1467 e1413 (2017).
12. Carr, P.A. et al. Enhanced multiplex genome engineering through co-operative oligonucleotide co-selection. *Nucleic Acids Res* **40**, e132 (2012).
13. DiCarlo, J.E. et al. Yeast oligo-mediated genome engineering (YOGI). *ACS Synth Biol* **2**, 741-749 (2013).
14. Costantino, N. & Court, D.L. Enhanced levels of lambda Red-mediated recombinants in mismatch repair mutants. *Proceedings of the National Academy of Sciences of the United States of America* **100**, 15748-15753 (2003).
15. Dekker, M., Brouwers, C. & te Riele, H. Targeted gene modification in mismatch-repair-deficient embryonic stem cells by single-stranded DNA oligonucleotides. *Nucleic Acids Res* **31**, e27 (2003).
16. Nyerges, A. et al. A highly precise and portable genome engineering method allows comparison of mutational effects across bacterial species. *Proceedings of the National Academy of Sciences of the United States of America* **113**, 2502-2507 (2016).
17. Aranda-Diaz, A., Mace, K., Zuleta, I., Harrigan, P. & El-Samad, H. Robust Synthetic Circuits for Two-Dimensional Control of Gene Expression in Yeast. *ACS Synth Biol* **6**, 545-554 (2017).
18. Wu, X.L. et al. Genome-wide landscape of position effects on heterogeneous gene expression in *Saccharomyces cerevisiae*. *Biotechnology for biofuels* **10**, 189 (2017).
19. Alani, E., Sokolsky, T., Studamire, B., Miret, J.J. & Lahue, R.S. Genetic and biochemical analysis of Msh2p-Msh6p: role of ATP hydrolysis and Msh2p-Msh6p subunit interactions in mismatch base pair recognition. *Mol Cell Biol* **17**, 2436-2447 (1997).
20. Shcherbakova, P.V. & Kunkel, T.A. Mutator phenotypes conferred by MLH1 overexpression and by heterozygosity for mlh1 mutations. *Mol Cell Biol* **19**, 3177-3183 (1999).
21. Das Gupta, R. & Kolodner, R.D. Novel dominant mutations in *Saccharomyces cerevisiae* MSH6. *Nat Genet* **24**, 53-56 (2000).
22. Lang, G.I. in *Genome Instability: Methods and Protocols*. (eds. M. Muzi-Falconi & G.W. Brown) 21-31 (Springer New York, New York, NY; 2018).

23. Cao, M., Tran, V.G. & Zhao, H. Unlocking nature's biosynthetic potential by directed genome evolution. *Curr Opin Biotechnol* **66**, 95-104 (2020).
24. Kaishima, M., Ishii, J., Matsuno, T., Fukuda, N. & Kondo, A. Expression of varied GFPs in *Saccharomyces cerevisiae*: codon optimization yields stronger than expected expression and fluorescence intensity. *Sci Rep* **6**, 35932 (2016).
25. Keppler-Ross, S., Noffz, C. & Dean, N. A new purple fluorescent color marker for genetic studies in *Saccharomyces cerevisiae* and *Candida albicans*. *Genetics* **179**, 705-710 (2008).
26. Subach, O.M., Cranfill, P.J., Davidson, M.W. & Verkhusha, V.V. An enhanced monomeric blue fluorescent protein with the high chemical stability of the chromophore. *PLoS One* **6**, e28674 (2011).
27. Liang, Z., Sunder, S., Nallasivam, S. & Wilson, T.E. Overhang polarity of chromosomal double-strand breaks impacts kinetics and fidelity of yeast non-homologous end joining. *Nucleic Acids Res* **44**, 2769-2781 (2016).
28. Chee, M.K. & Haase, S.B. New and Redesigned pRS Plasmid Shuttle Vectors for Genetic Manipulation of *Saccharomyces cerevisiae*. *G3* **2**, 515-526 (2012).
29. Brachmann, C.B. et al. Designer deletion strains derived from *Saccharomyces cerevisiae* S288C: a useful set of strains and plasmids for PCR-mediated gene disruption and other applications. *Yeast* **14**, 115-132 (1998).
30. Gibson, D.G. Enzymatic assembly of overlapping DNA fragments. *Methods Enzymol* **498**, 349-361 (2011).
31. Lang, G.I. & Murray, A.W. Estimating the per-base-pair mutation rate in the yeast *Saccharomyces cerevisiae*. *Genetics* **178**, 67-82 (2008).

Extended Data Table 1: Subunit variants of DNA mismatch repair MutS complexes tested in this study.

MMR gene	Variant	Mutated domain	Protein biochemistry	Reported spontaneous mutation rate ^a (vs. wild-type)	Sources
MSH2	Wild-type	-	-	Unchanged ^b	Alani et al, <i>Mol Cell Biol.</i> 1997 ¹⁹
	G693D	ATPase (MSH2)	Defective ATP binding	~50-fold ^b	
	G855D		Defective ATP binding, hydrolysis and MutS-DNA complex formation		
	G693D, G855D (GGDD)		Combined effects of two single mutants		
MSH6	Wild-type	-	-	Unchanged ^b	Gupta et al, <i>Nat Genet.</i> 2000 ²¹
	S1036P	ATPase (MSH6)	Defective ATP hydrolysis	~15-fold ^b	
	G1067D	Domain interacting with ATPase (MSH2)	Defective ATP hydrolysis and MutS-DNA complex formation		
	G1142D				
MLH1	Wild-type	-	Imbalanced MLH1-PSM1 stoichiometry	~13-fold ^b	Shcherbakova et al, <i>Mol Cell Biol.</i> 1999 ²⁰
	G64R	ATPase (MLH1)	Defective ATP binding and hydrolysis	~6-fold ^c	
	I65N				
	T114M				

^a Based on reported data of the referenced literatures, showing the fold increases of mutation rate upon overexpression of specific MMR proteins as compared to the corresponding wild-type strains.

^b Overexpressed from high-copy 2 μ plasmids. Mutation rates of *CAN1* gene were measured by quantification of canavanine resistance colonies.

^c Expressed from the endogenous *MLH1* locus. Mutation rates of *lys2::InsE-A14* locus were measured by quantification of Lys⁺ colonies.

Extended Data Table 2: Influence of MMR proficiency on eMAGE genome editing and spontaneous mutations.


MMR status	A	B		C	D	E
	Spontaneous mutation rate (<i>ura3</i> per cell per division)	Est. number of spontaneous mutations (per cell)		Avg. number of on-target edits (per cell per eMAGE)	Approx. number of URA3, ADE2 cells (electrop. cells: 10 ⁹)	Total number of eMAGE edited sites (edited sites=C×D)
		eMAGE ^a	10-day cultivation ^b			
Wild-type	5.45×10⁻⁸	0.05	0.10	1.4	~1.5×10 ³	2.1×10 ³
<i>msh2Δ</i>	1.38×10⁻⁶	1.37	2.50	1.7	~1.5×10 ⁴	2.6×10 ⁴
Wild-type + p[MSH2-GGDD]	8.02×10⁻⁸ (uninduced) 1.93×10⁻⁶ (β-E: 0.6 μM)	0.33	0.15	1.7	~1.5×10 ⁴	2.6×10 ⁴

^a One round of eMAGE involves ~66 cell divisions; MSH2-GGDD was induced for 18 hours (~9 cell divisions). Detailed calculations in Method.


^b Est. cultivation time of eMAGE relevant applications (e.g., metabolic variant selection or engineered protein production).

Column **A** shows spontaneous mutation rate of yeast strains determined by fluctuation analysis of *URA3* loss-of-function mutagenesis. The MMR fidelity of the yeast strain carrying p[MSH2-GGDD] (episomal vector of MSH2-GGDD inducible expression) can be toggled between the levels of wild-type (uninduced) and *msh2Δ* (β-E: 0.6 μM) cells. Mutation rates of the wild-type and *msh2Δ* strains observed in our study are consistent with previous reports³¹. Column **B** shows the estimated number of spontaneous mutations in the compared strains. Because MSH2-GGDD is only expressed prior to ssODN electroporation for 18 hours out of the 5.5 days of total cultivation time needed for one round of eMAGE (2-day of isolated colony forming from frozen glycerol stock and 3.5-day of eMAGE protocol time), the transient expression scheme greatly reduces the accumulated spontaneous mutations during one round of eMAGE by >4-fold as compared to *msh2Δ* cells, to a level similar to the MMR-proficient (wild-type) cells (column **B**, eMAGE). Notably, eMAGE strains often go through multiple rounds of editing and are used in applications require prolonged cultivation. Therefore, wild-type levels of


genome stability of the eMAGE strain carrying p[MSH2-GGDD] lead to a substantial 17-fold reduction of secondary mutations during cell cultivation (column **B**, 10-day cultivation). Meanwhile, tunable expression of MSH2-GGDD allows *msh2Δ* levels of high editing efficiency (column **C**) and provides a 10-fold increase of double edited URA3, ADE2 cells (column **D**), resulting in significantly increased genomic diversification up to 10⁴ unique variants as compared to MMR wild-type strain (column **E**). β-E: β-estradiol. Data sources and information of the calculations involved in this table can be found in Method.




Extended Data Fig. 1: Effect of ssODN concentration and modification on frequency of edited cells and cell viability. **a**, Frequency of RFP positive cells in ssODN-transfected population prior to -Ura selection under different ssODN concentrations and ratios used in **Fig. 1e**. It positively correlates with the concentration of RFP-ssODN. **b**, Frequency of URA3 cells decreases with URA3-ssODN concentration. **c**, Cell survival of selective conditions used in **Fig. 1e**, showing decreased viability after electroporation with increased ssODN concentration. Cell viability data were normalized to untreated cells (100 % viable). **d**, Protecting ssODN from exonuclease degradation by modifying the last 4 nt of its 5' and 3' ends with phosphorothioate bonds does not result in major enhancement of eMAGE ARF as compared to unprotected ssODNs. All values represent mean $\pm$ SD for at least three replicates. p values of multiple-group comparisons from ordinary one-way ANOVA Dunnett's test and p values of two-group comparisons from unpaired t-test. ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001.



Extended Data Fig. 2: Comparison of three dual-marker placement strategies. **a**, eMAGE reporter used in this analysis containing the same frameshifted fluorescent reporter genes as the one in **Fig. 2a**. To simulate the three possible architectures for co-selection marker placement: (i) proximal to ARS, (ii) distal to ARS, and (iii) flanking targeted loci, the flow cytometry data collected from the same experiments were analyzed as follows: two of the three fluorescent markers were used as parental gates to select the cells with either single or double positive fluorescent phenotypes. The percentage of these gated cells that are positive for the remaining (third) fluorescent gene represents the eMAGE co-selection ARF. **b**, Comparison of eMAGE ARF using co-selection with either a single or dual fluorescent marker in the above three placement configurations. In all scenarios, co-selection with two markers (last bar) yields higher eMAGE ARF compared to co-selection with only a single marker. Architecture (iii), in which the co-selection markers flank the targeted loci, resulted in the highest ARF gain among the tested dual-marker placement strategies. All values represent mean $\pm$ SD for at least three replicates. p values from ordinary one-way ANOVA Dunnett's test. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.



Extended Data Fig. 3: MMR deficiency promotes eMAGE editing and benefits implementation of dual-marker co-selection. a, Comparison of MMR wild-type (WT) and *MSH2* knockout (*msh2Δ*) strains for their frameshift correction frequency of each marker in the eMAGE reporter shown in **Fig. 2a**. Deletion of *MSH2* confers a three to five-fold increase in frameshift correction frequency and a 10-fold increase of double-edited URA3, ADE2 cells. All values represent mean $\pm$ SD for at least three replicates. p values from unpaired t-test. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.



Extended Data Fig. 4: Engineering tunable expression of dominant negative mutants to modulate MMR fidelity during eMAGE editing. **a**, RFP induction over 24 hours with titration of β -estradiol concentration reveals a robust dose-response and time-dependent expression curve. **b**, Selected MMR subunit variants of three wild-type proteins and nine dominant negative mutants overexpressed using our improved β -estradiol inducible system from high-copy 2 μ plasmids (see plasmids used in this study in **Supplementary Table 2**). This vector allows inducible expression of up to two MMR subunits simultaneously using the bidirectional *Gal1-10* promoter upon supplying β -estradiol in growth media of strains with GEM expression. Expression of subunit variants from episomal vector was induced with β -estradiol for 18 hours prior to ssODN electroporation. After electroporation cells were recovered overnight in medium without β -estradiol and analyzed by flow cytometry without co-selection. Notably, this vector is also compatible with conventional galactose induction providing flexibility for yeast strains

without a pre-integrated GEM cassette. However, galactose induction is not preferable due to the expression level of MMR-DN is more difficult to be controlled and it requires carbon source changes that could perturb cell growth and increase protocol time. **c**, Influence of 12 MMR subunit variants on ssODN-mediated frameshift correction frequency in three fluorescent reporter genes shown in **Fig. 2a**, as compared to MMR-proficient (WT) and MMR-deficient (*msh2Δ*) cells. Expression of subunit variants from episomal vector was induced with 0.4 μM β-estradiol for 18 hours (~50% of maximum overexpression) prior to ssODN electroporation. **d**, Modulation of MMR fidelity by titrating MSH2-GGDD and MLH1-WT expression with different β-estradiol concentrations. p values of multiple-group comparisons from ordinary one-way ANOVA Dunnett's test and p values of two-group comparisons from unpaired t-test. ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001.

Supplementary Information

Supplementary Table 1: Yeast Strains used in this study.

Supplementary Table 2: Plasmids used in this study.

Supplementary Table 3: ssODNs and selective PCR primers used in this study.

Supplementary File 1: DNA sequence files of important genomic loci and plasmids.